SPL Share Price

Open 0.74 Change Price %
High 0.75 1 Day 0.00 0.00
Low 0.73 1 Week 0.08 12.12
Close 0.74 1 Month 0.02 2.78
Volume 322768 1 Year -0.04 -5.13
52 Week High 0.79
52 Week Low 0.54
SPL Important Levels
Resistance 2 0.76
Resistance 1 0.75
Pivot 0.74
Support 1 0.73
Support 2 0.72
ASX Australia Most Active Stocks
AGO 0.02 0.00%
AGO 0.02 0.00%
AGO 0.02 0.00%
AKK 0.01 0.00%
TON 0.09 -10.00%
TON 0.09 -10.00%
TON 0.09 -10.00%
FAR 0.07 0.00%
FAR 0.07 0.00%
FAR 0.07 0.00%
More..
ASX Australia Top Gainers Stocks
KSO 0.40 3900.00%
IRM 0.03 50.00%
IRM 0.03 50.00%
IRM 0.03 50.00%
PMQ 0.03 50.00%
OMH 0.18 28.57%
SRZ 0.05 25.00%
SRZ 0.05 25.00%
HGO 0.05 25.00%
HGO 0.05 25.00%
More..
ASX Australia Top Losers Stocks
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
TCQ 0.27 -73.53%
RXL 0.01 -50.00%
RXL 0.01 -50.00%
RXL 0.01 -50.00%
GBA 0.02 -33.33%
DAU 0.02 -33.33%
More..

Starpharma Holdings Ltd (ASX: SPL)

SPL Technical Analysis 5
As on 7th Dec 2016 SPL Share Price closed @ 0.74 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 0.67 & Strong Buy for SHORT-TERM with Stoploss of 0.68 we also expect STOCK to react on Following IMPORTANT LEVELS.
SPL Target for December
1st Target up-side 0.72
2nd Target up-side 0.76
3rd Target up-side 0.8
1st Target down-side 0.6
2nd Target down-side 0.56
3rd Target down-side 0.52
SPL Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.starpharma.com
SPL Address
SPL
Baker IDI Building
75 Commercial Road
Melbourne, VIC 3004
Australia
Phone: 61 3 8532 2700
Fax: 61 3 9510 5955
Interactive Technical Analysis Chart Starpharma Holdings Ltd ( SPL ASX Australia )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Starpharma Holdings Ltd
SPL Business Profile
Starpharma Holdings Limited researches, develops, and commercializes dendrimer products for pharmaceutical, life-science, and other applications primarily in Australia. The company focuses on the development of its topical vaginal microbicide VivaGel as a condom coating for the treatment and prevention of bacterial vaginosis, as well as for the prevention of sexually transmitted infections, including genital herpes and HIV. It is also engaged in exploring dendrimer opportunities in materials science with applications in various areas, such as cosmetics, agrochemicals, and coatings. The company was founded in 1996 and is headquartered in Melbourne, Australia.